Skip to Main Content

Vertex

Vertex Pharmaceuticals is a Boston-based biopharmaceutical company well-known for its groundbreaking work against cystic fibrosis and strong financial performance. It is currently researching treatments for chronic pain, diabetes and more.

Latest

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

A deep dive on Makary, Vertex’s pain data, & 2025 predictions

Biotech Matthew Herper and Jonathan Wosen

STAT Plus: Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study

Adam's Take Adam Feuerstein

STAT Plus: Who stood out as Best Biopharma CEO of 2024?

Biotech Jonathan Wosen

STAT Plus: Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain

Biotech Jason Mast

STAT Plus: As U.S. efforts stall, China pushes ahead with CRISPR treatments for muscular dystrophy

Biotech Adam Feuerstein

STAT Plus: The business of CRISPR’d medicine: Not great

Biotech Megan Molteni

Vertex sues U.S. government over access to fertility support services for Casgevy patients

Health Elizabeth Cooney

STAT Plus: Vertex reports positive results in stem cell trial for type 1 diabetes

All Coverage

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s big deal, biotech’s red numbers, & an industry history lesson

Biotech Matthew Herper and Adam Feuerstein

STAT Plus: Vertex to buy Alpine Immune Sciences for $4.9 billion

advertisement

Biotech Catherine Carlock and Jonathan Saltzman — the Boston Globe

STAT Plus: Vertex Pharmaceuticals is considering relocating its headquarters

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

Biotech Jonathan Wosen

STAT Plus: Vertex’s closely watched pain relief drug succeeds in late-stage trials — with a catch

The Readout Damian Garde

STAT Plus: No pain data yet from Vertex, and sky high deal expectations at JPM 2024

Health Jason Mast

After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future

Biotech Jason Mast

STAT Plus: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in

Biotech Jonathan Wosen

STAT Plus: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers

Biotech Allison DeAngelis

STAT Plus: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

Pharmalot Ed Silverman

STAT Plus: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines

Pharmalot Ed Silverman

STAT Plus: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough

Pharmalot Ed Silverman

STAT Plus: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines

Pharmalot Ed Silverman

STAT Plus: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries

Health Jonathan Wosen

STAT Plus: Vertex non-opioid therapy reduced pain in mid-stage trials, study shows

First Opinion Jayasree K. Iyer

Sickle cell cures are coming. African children can’t be left behind

Pharmalot Ed Silverman

STAT Plus: Brazilian government advisory committee says a Vertex cystic fibrosis drug is not cost-effective and should not be reimbursed

Biotech Adam Feuerstein

STAT Plus: Vertex, CRISPR Therapeutics inch ahead of rival for genetic fix to sickle cell disease

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Vertex vs. insurers, Moderna’s future, & biotech’s long winter

Pharmalot Ed Silverman

STAT Plus: Angry at Vertex pricing of cystic fibrosis drugs, families in four countries seek to override patents